Establishing 18F-PBR06 PET Imaging as a Viable Pharmacodynamic Endpoint in MSA

Completed · Phase 1/Phase 2

Conditions studied: MSA

In brief

The specific aims of the study are: Primary: To determine the presence and regional distribution of microglial activation, as assessed by \[F-18\]PBR06 PET, in subjects with MSA as compared to healthy controls, at baseline and at 9 months follow-up. Secondary: To assess the relationship between microglial activation and clinical progression at baseline and follow-up. Hypothesis: The working hypothesis is that there is microglial activation in Multiple System Atrophy and that the presence and regional distribution of microglial activation is different in MSA versus healthy controls and correlates with disease severity and comorbidities.

Key facts

Study ID

NCT03033680

Run by

Brigham and Women's Hospital

People needed

17

Starts

2017-03-24

Expected to finish

2021-01-15

Last updated by the study team

2021-04-26

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Probable MSA clinical diagnosis.
• Male and female subjects age 18 to 70 years.
• Motor symptom onset <2 years prior.
• Available brain MRI.

You may not qualify if…

• Individuals with a known alternate neurologic disorder, previous head injury, or substance abuse.
• Individuals with bipolar disease and schizophrenia
• Concurrent medical conditions that contraindicate study procedures.
• Women who are pregnant or nursing. Also, any woman who is seeking to become pregnant or suspects she is pregnant will be excluded from enrollment.
• Claustrophobia
• Corticosteroid treatment in the past four weeks
• Non-MRI compatible implanted devices
• Low Affinity binders

Where it is running

• Movement Disorders Clinic, 60 Fenwood Road — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.